抗癌治疗疗效的祖先差异及其潜在的基因组和分子改变。
Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.
作者信息
Luo Mei, Yang Jingwen, Schäffer Alejandro A, Chen Chengxuan, Liu Yuan, Chen Yamei, Lin Chunru, Diao Lixia, Zang Yong, Lou Yanyan, Salman Huda, Mills Gordon B, Ruppin Eytan, Han Leng
机构信息
Brown Center for Immunotherapy, School of Medicine, Indiana University, Indianapolis, Indiana.
Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, Indiana.
出版信息
Cancer Discov. 2025 Mar 3;15(3):511-529. doi: 10.1158/2159-8290.CD-24-0827.
Abstract
Our study charts a global landscape of ancestry-associated differences in therapeutic efficacy, highlighting the importance of considering ancestry in anticancer therapies.
摘要
我们的研究描绘了一幅治疗效果中与血统相关差异的全球图景，突出了在抗癌治疗中考虑血统的重要性。
相似文献
1
Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.
Cancer Discov. 2025 Mar 3;15(3):511-529. doi: 10.1158/2159-8290.CD-24-0827.
2
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.
Genome Med. 2018 May 31;10(1):41. doi: 10.1186/s13073-018-0546-1.
3
Genetic Ancestry-Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies.
JAMA Oncol. 2025 Mar 1;11(3):310-316. doi: 10.1001/jamaoncol.2024.5794.
4
A decision support framework for genomically informed investigational cancer therapy.
J Natl Cancer Inst. 2015 Apr 11;107(7). doi: 10.1093/jnci/djv098. Print 2015 Jul.
5
The nationwide survey of Japanese public opinion about off-label use of anticancer drugs recommended by comprehensive genomic profiling.
Int J Clin Oncol. 2025 Jul 18. doi: 10.1007/s10147-025-02809-y.
6
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.
Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025.
7
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion.
Adv Ther. 2025 May 22. doi: 10.1007/s12325-025-03195-7.
8
Phytochemicals in Cancer Therapy: A Structured Review of Mechanisms, Challenges, and Progress in Personalized Treatment.
Chem Biodivers. 2025 Aug;22(8):e202402479. doi: 10.1002/cbdv.202402479. Epub 2025 Jun 11.
9
Deep learning-driven drug response prediction and mechanistic insights in cancer genomics.
Sci Rep. 2025 Jul 1;15(1):20824. doi: 10.1038/s41598-025-91571-2.
10
Anticancer efficacy of Spiruchostatin A: current insights into histone deacetylase inhibition and oncologic applications.
Eur J Med Res. 2025 Mar 14;30(1):169. doi: 10.1186/s40001-025-02401-0.
引用本文的文献
1
Advancing equitable access to innovation in breast cancer.
NPJ Breast Cancer. 2025 Jul 10;11(1):71. doi: 10.1038/s41523-025-00768-1.
2
Spatial and temporal dynamics in progressive gallbladder cancer.
Nat Genet. 2025 Jun 26. doi: 10.1038/s41588-025-02232-z.
本文引用的文献
1
Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.
Aging (Albany NY). 2024 Jan 8;16(1):550-567. doi: 10.18632/aging.205395.
2
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.
Nat Genet. 2023 Dec;55(12):2065-2074. doi: 10.1038/s41588-023-01534-4. Epub 2023 Nov 9.
3
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
Cancer Cell. 2023 Nov 13;41(11):1963-1971.e3. doi: 10.1016/j.ccell.2023.10.003. Epub 2023 Oct 26.
4
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.
Cancer Discov. 2024 Jan 12;14(1):49-65. doi: 10.1158/2159-8290.CD-23-0467.
5
Expanding PROTACtable genome universe of E3 ligases.
Nat Commun. 2023 Oct 16;14(1):6509. doi: 10.1038/s41467-023-42233-2.
6
Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study.
Signal Transduct Target Ther. 2023 Sep 29;8(1):363. doi: 10.1038/s41392-023-01596-0.
7
A multi-omics perspective of CAR T cell therapy.
Clin Transl Med. 2023 May;13(5):e1274. doi: 10.1002/ctm2.1274.
8
Pan-cancer whole-genome comparison of primary and metastatic solid tumours.
Nature. 2023 Jun;618(7964):333-341. doi: 10.1038/s41586-023-06054-z. Epub 2023 May 10.
9
CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
Curr Oncol Rep. 2023 May;25(5):479-489. doi: 10.1007/s11912-023-01380-x. Epub 2023 Feb 28.
10
Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation.
Cell Chem Biol. 2023 Feb 8. doi: 10.1016/j.chembiol.2023.01.007.
Zotero 插件